Assessment of the Early Effects of 5,6-Dimethylxanthenone-4-Acetic Acid Using Macromolecular Contrast Media-Enhanced Magnetic Resonance Imaging: Ectopic Versus Orthotopic Tumors

International Journal of Radiation Oncology Biology Physics

Volumn 72, Issue 4, 2008, Pages 1198-1207

  Seshadri, Mukund ^a   Bellnier, David A ^a   Cheney, Richard T ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

5,6 Dimethylxanthenone 4 acetic acid (DMXAA); ASA404; Macromolecular contrast media (MMCM) enhanced magnetic resonance imaging (MMCM MRI); Vascular disrupting agent (VDA)

Indexed keywords

ACETIC ACID; ACIDS; ATOMS; CONTRAST MEDIA; GLYCOPROTEINS; MACROMOLECULES; MACROPHAGES; MAGNETIC MATERIALS; MAGNETIC RESONANCE; MAGNETIC RESONANCE IMAGING; METAL ANALYSIS; ONCOLOGY; PH; PH EFFECTS; RESONANCE;

5,6-DIMETHYLXANTHENONE-4-ACETIC ACID (DMXAA); AFTER-TREATMENT; ANTIVASCULAR; ASA404; CONSISTENT; CONTRAST AGENTS; CYTOKINE INDUCTIONS; EARLY EFFECTS; GREAT-ER; IMMUNOSORBENT ASSAYS; INTRAVASCULAR; LONGITUDINAL RELAXATIONS; MACROMOLECULAR CONTRAST MEDIA (MMCM)-ENHANCED MAGNETIC RESONANCE IMAGING (MMCM-MRI); MICROENVIRONMENT; NORMAL TISSUES; ORTHOTOPIC; QUANTITATIVE ESTIMATES; TUMOR NECROSIS FACTORS; TUMOR PERFUSIONS; VASCULAR DAMAGES; VASCULAR DISRUPTING AGENT (VDA); VASCULAR ENDOTHELIAL GROWTH FACTORS;

TUMORS;

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ALBUMIN GADOPENTETATE DIMEGLUMINE; CD31 ANTIGEN; CONTRAST MEDIUM; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROSARCOMA; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MACROMOLECULE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TISSUE LEVEL; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CONTRAST MEDIA; FEMALE; FIBROSARCOMA; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; TREATMENT OUTCOME; XANTHONES;

EID: 54049136590     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.07.043     Document Type: Article

References (34)

1. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29 (2002) 15-18
2. Ruoslahti E. Specialization of tumor vasculature. Nat Rev Cancer 2 (2002) 83-90
3. McKeage M.J., Fong P., Jeffery M., et al. 5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: A phase I safety study of a vascular disrupting agent. Clin Cancer Res 12 (2006) 1776-1784
4. Pili R., and Rosenthal M. AS1404-203 study group investigators. Randomized phase II study of docetaxel with or without DMXAA (AS1404) in hormone-refractory metastatic prostate cancer (HRMPC). [Abstract]. J Clin Oncol 25 (2007) 5115
5. Tozer G.M., Kanthou C., and Baguley B.C. Disrupting tumour blood vessels. Nat Rev Cancer 5 (2005) 423-435
6. Padhani A.R. MRI for assessing antivascular cancer treatments. Br J Radiol 76 Suppl. (2003) S60-S80
7. O'Connor J.P., Jackson A., Parker G.J., et al. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 96 (2007) 189-195
8. Brasch R., Pham C., Shames D., et al. Assessing tumor angiogenesis using macromolecular MR imaging contrast media. J Magn Reson Imaging 7 (1997) 68-74
9. Barrett T., Kobayashi H., Brechbiel M., et al. Macromolecular MRI contrast agents for imaging tumor angiogenesis. Eur J Radiol 60 (2006) 353-366
10. Turetschek K., Preda A., Novikov V., et al. Tumor microvascular changes in antiangiogenic treatment: Assessment by magnetic resonance contrast media of different molecular weights. J Magn Reson Imaging 20 (2004) 138-144
11. Daldrup H., Shames D.M., Wendland M., et al. Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: Comparison of macromolecular and small-molecular contrast media. AJR Am J Radiol 171 (1998) 941-949
12. Fidler I.J. Angiogenic heterogeneity: Regulation of neoplastic angiogenesis by the organ microenvironment. J Natl Cancer Inst 93 (2001) 1040-1041
13. Jung Y.D., Ahmad S.A., Akagi Y., et al. Role of the tumor microenvironment in mediating response to anti-angiogenic therapy. Cancer Metastasis Rev 19 (2000) 147-157
14. Seshadri M., Spernyak J.A., Maier P.G., et al. Visualizing the acute effects of vascular-targeted therapy in vivo using intravital microscopy and magnetic resonance imaging: Correlation with endothelial apoptosis, cytokine induction and treatment outcome. Neoplasia 9 (2007) 128-135
15. Ogan M., Schmiedl U., Moseley M., et al. Albumin labeled with Gd-DTPA: An intravascular enhancing agent for magnetic resonance blood pool imaging: Preparation and characterization. Invest Radiol 22 (1987) 665-671
16. Seshadri M., Mazurchuk R., Spernyak J.A., et al. Activity of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid against human head and neck carcinoma xenografts. Neoplasia 8 (2006) 534-542
17. Baguley B.C., and Ching L.-M. DMXAA: An antivascular agent with multiple host responses. Int J Radiat Oncol Biol Phys 54 (2002) 1503-1511
18. Joseph W.R., Cao Z., Mountjoy K.G., et al. Stimulation of tumours to synthesize tumor necrosis factor-α in situ using 5,6-dimethylxanthenone-4-acetic acid: A novel approach to cancer therapy. Cancer Res 59 (1999) 633-638
19. Kim Y.R., Yudina A., Figueiredo J., et al. Detection of early antiangiogenic effects in human colon adenocarcinoma xenografts: In vivo changes of tumor blood volume in response to experimental VEGFR tyrosine kinase inhibitor. Cancer Res 65 (2005) 9253-9260
20. Zechmann C.M., Woenne E.C., Brix G., et al. Impact of stroma on the growth, microcirculation, and metabolism of experimental prostate tumors. Neoplasia 9 (2007) 57-67
21. Liu J.J., Ching L.M., Goldthorpe M., et al. Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours. Cancer Chemother Pharmacol 59 (2007) 661-669
22. Watanabe N., Niitsu Y., Umeno H., et al. Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res 48 (1988) 2179-2183
23. Tang J.S., Choy G., Bernardo M., et al. Dynamic contrast-enhanced magnetic resonance imaging in the assessment of early response to tumor necrosis factor alpha in a colon carcinoma model. Invest Radiol 41 (2006) 691-696
24. Ching L.M., Goldsmith D., Joseph W.R., et al. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice. Cancer Res 59 (1999) 3304-3307
25. Zhao L., Ching L.M., Kestell P., et al. The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice. Br J Cancer 87 (2002) 465-470
26. Ching L.M., Cao Z., Kieda C., et al. Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 86 (2002) 1937-1942
27. McPhail L.D., McIntyre D.J., Ludwig C., et al. Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis. Neoplasia 8 (2006) 199-206
28. Woon S.T., Hung S.S., Wu D.C., et al. NF-kappaB-independent induction of endothelial cell apoptosis by the vascular disrupting agent DMXAA. Anticancer Res 27 (2007) 327-334
29. Zhao L., Marshall E.S., Kelland L.R., et al. Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Invest New Drugs 25 (2007) 271-276
30. Galbraith S.M., Rustin G.J., Lodge M.A., et al. Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 20 (2002) 3826-3840
31. Galbraith S.M., Maxwell R.J., Lodge M.A., et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 21 (2003) 2831-2842
32. Heilmann M., Kiessling F., Enderlin M., et al. Determination of pharmacokinetic parameters in DCE MRI: Consequence of nonlinearity between contrast agent concentration and signal intensity. Invest Radiol 41 (2006) 536-543
33. Preda A., Novikov V., Möglich M., et al. MRI monitoring of Avastin antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer. J Magn Reson Imaging 20 (2004) 865-873
34. Barrett T., Brechbiel M., Bernardo M., et al. MRI of tumor angiogenesis. J Magn Reson Imaging 26 (2007) 235-249